Chardan Capital reaffirmed their hold rating on shares of Vascular Biogenics (NASDAQ:VBLT) in a research report report published on Tuesday, AnalystRatings.com reports. The firm currently has a $3.00 target price on the biopharmaceutical company’s stock.

A number of other equities analysts have also weighed in on VBLT. HC Wainwright restated a buy rating and set a $3.00 target price on shares of Vascular Biogenics in a research report on Thursday, May 16th. Zacks Investment Research lowered shares of Vascular Biogenics from a buy rating to a hold rating in a research report on Thursday, May 30th. ValuEngine upgraded shares of Vascular Biogenics from a sell rating to a hold rating in a research report on Thursday, August 1st. CIBC initiated coverage on shares of Vascular Biogenics in a research report on Thursday, June 27th. They set an outperform rating for the company. Finally, Oppenheimer initiated coverage on shares of Vascular Biogenics in a research report on Thursday, June 27th. They set an outperform rating and a $2.00 price objective for the company. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company currently has an average rating of Buy and a consensus target price of $2.38.

Shares of NASDAQ:VBLT opened at $1.18 on Tuesday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 8.35 and a current ratio of 8.35. The firm has a fifty day moving average price of $1.30 and a 200 day moving average price of $1.37. Vascular Biogenics has a fifty-two week low of $0.60 and a fifty-two week high of $1.90. The firm has a market cap of $44.85 million, a price-to-earnings ratio of -1.90 and a beta of -0.33.

Vascular Biogenics (NASDAQ:VBLT) last issued its earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.13). Vascular Biogenics had a negative net margin of 3,021.20% and a negative return on equity of 34.08%. The firm had revenue of $0.14 million during the quarter, compared to analyst estimates of $0.25 million. As a group, research analysts predict that Vascular Biogenics will post -0.53 earnings per share for the current year.

Hedge funds have recently added to or reduced their stakes in the business. First Republic Investment Management Inc. raised its position in shares of Vascular Biogenics by 7.4% during the 1st quarter. First Republic Investment Management Inc. now owns 145,000 shares of the biopharmaceutical company’s stock valued at $220,000 after buying an additional 10,000 shares in the last quarter. Menta Capital LLC purchased a new stake in shares of Vascular Biogenics during the 1st quarter valued at $35,000. Athena Capital Advisors LLC purchased a new stake in shares of Vascular Biogenics during the 1st quarter valued at $25,000. Finally, Morgan Stanley raised its position in shares of Vascular Biogenics by 6.5% during the 2nd quarter. Morgan Stanley now owns 295,012 shares of the biopharmaceutical company’s stock valued at $383,000 after buying an additional 17,900 shares in the last quarter. Institutional investors and hedge funds own 6.80% of the company’s stock.

About Vascular Biogenics

Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels.

Featured Story: Municipal Bonds

Receive News & Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related companies with MarketBeat.com's FREE daily email newsletter.